Ribavirin

Ribavirin, also known as tribavirin, is an antiviral medication used to treat RSV infection, hepatitis C, and viral hemorrhagic fever.

Ribavirin

Ribavirin; 36791-04-5; Tribavirin; Virazole; Rebetol

Rebetol, Ribamac, Ribapro, Ribavin, Rivirin, Virazide

1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide

Oral absorption

It is a member of the nucleoside antimetabolite drugs that interfere with duplication of the viral genetic material. By inhibiting the activity of the enzyme RNA dependent RNA polymerase, due to its resemblence to building blocks of the RNA molecules. Ribavirin mediates direct antiviral activity against a number of DNA and RNA viruses by increasing the mutation frequency in the genomes of several RNA viruses.

As recommended by physician.

Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR).

BP fall, haemolytic anaemia, dyspepsia, nausea, dyspnoea, irritability, skin rashes, pruritus and headache, pharyngitis, anorexia, abdominal cramps, fatigue, metallic taste, increased thirst, GI complaints, mood changes, insomnia. Deterioration in pulmonary function, bacterial pneumonia and pneumothorax, reticulocytosis, cardiac arrest, anaemia, reticulocytosis, conjunctivitis, skin rash. Eye irritation due to deposited drug (infrequent). Increased serum bilirubin and uric acid.

• Increased risk of severe neutropenia and anaemia when used with zidovudine.
• May worsen neutropenia induced by interferon alfa.
• When used with didanosine risk of fatal hepatic failure, peripheral neuropathy and pancreatitis.
• May increase risk of adverse effects when used with nucleoside reverse transcriptase inhibitors.

• Hypersensitivity.
• Pregnancy and lactation.
• Unstable cardiac disease, haemoglobinopathies or CrCl <50 ml/min.
• Severe hepatic impairment or decompensated liver cirrhosis.
• Men whose female partners are pregnant.
• Children and adolescents with a history of, or existing psychiatric disorders.

Store at 15-30°C.

Molecular weight

244.2047

Molecular formula

C8H12N4O5

CAS number

36791-04-5

Precautions

• Patients with extensive hepatic fibrosis; renal impairment; anaemias.
• Monitor CBC at the start of, and regularly during treatment.
• Ensure contraception during treatment and for at least 6 mth after treatment cessation in women and female partners of male patients.
• Increased risk of fatal and nonfatal MI in patients with anaemia.